Judi Kasem1, Umar Wazir1,2, Kefah Mokbel3. 1. London Breast Institute, Princess Grace Hospital, London, U.K. 2. Department of General Surgery, Khyber Teaching Hospital, Peshawar, Pakistan. 3. London Breast Institute, Princess Grace Hospital, London, U.K.; kefah.mokbel@hotmail.com.
Abstract
BACKGROUND/AIM: Axillary lymph node (ALN) status plays a key role in the staging of breast cancer. Positron Emission Tomography/Computed Tomography (PET/CT) using 18-Fluorodeoxyglucose (18FDG) can visualise ALN metastasis. However, its utility compared to current methods is unclear. We systematically reviewed the role of 18FDG PET/CT in breast cancer staging. MATERIALS AND METHODS: PubMed, Ovid and Cochrane were searched systematically up until August 2020. Included papers had true positive (TP), false positive (FP), true negative (TN) and false negative (FN) rates, sensitivity, specificity, accuracy, positive (PPV) and negative predictive value (NPV). RESULTS: Nine studies (n=1486) were included, showing: i) sensitivity=52.2%, ii) specificity=91.6%, iii) PPV=77.8%, iv) NPV=77.2, and v) accuracy=77.3%. CONCLUSION: 18FDG-PET/CT has a low sensitivity but high specificity for ALN disease. Therefore, ultrasound-guided biopsy could be considered in a positive CT/PET. Modest accuracy prohibits the use of 18FDG-PET/CT alone in axillary staging. Prospective research using standardised protocols and quantitative cut-off points is warranted. Copyright
BACKGROUND/AIM: Axillary lymph node (ALN) status plays a key role in the staging of breast cancer. Positron Emission Tomography/Computed Tomography (PET/CT) using 18-Fluorodeoxyglucose (18FDG) can visualise ALN metastasis. However, its utility compared to current methods is unclear. We systematically reviewed the role of 18FDG PET/CT in breast cancer staging. MATERIALS AND METHODS: PubMed, Ovid and Cochrane were searched systematically up until August 2020. Included papers had true positive (TP), false positive (FP), true negative (TN) and false negative (FN) rates, sensitivity, specificity, accuracy, positive (PPV) and negative predictive value (NPV). RESULTS: Nine studies (n=1486) were included, showing: i) sensitivity=52.2%, ii) specificity=91.6%, iii) PPV=77.8%, iv) NPV=77.2, and v) accuracy=77.3%. CONCLUSION:18FDG-PET/CT has a low sensitivity but high specificity for ALN disease. Therefore, ultrasound-guided biopsy could be considered in a positive CT/PET. Modest accuracy prohibits the use of 18FDG-PET/CT alone in axillary staging. Prospective research using standardised protocols and quantitative cut-off points is warranted. Copyright
Authors: D J P van Uden; M W Prins; S Siesling; J H W de Wilt; C F J M Blanken-Peeters; E H J G Aarntzen Journal: Crit Rev Oncol Hematol Date: 2020-05-07 Impact factor: 6.312
Authors: Johannes Grueneisen; James Nagarajah; Christian Buchbender; Oliver Hoffmann; Benedikt Michael Schaarschmidt; Thorsten Poeppel; Michael Forsting; Harald H Quick; Lale Umutlu; Sonja Kinner Journal: Invest Radiol Date: 2015-08 Impact factor: 6.016
Authors: U Veronesi; C De Cicco; V E Galimberti; J R Fernandez; N Rotmensz; G Viale; G Spano; A Luini; M Intra; P Veronesi; A Berrettini; G Paganelli Journal: Ann Oncol Date: 2006-12-12 Impact factor: 32.976
Authors: Matthew F Covington; Bhasker R Koppula; Gabriel C Fine; Ahmed Ebada Salem; Richard H Wiggins; John M Hoffman; Kathryn A Morton Journal: Cancers (Basel) Date: 2022-05-29 Impact factor: 6.575